SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is seeing intense discussion following a steep price drop triggered by a Raymond James downgrade related to its SCAR program recompetition, sparking community shock and claims of manipulation, though some view it as an overreaction given persistent defense sector demand.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid a surging optical interconnect sector, driven by NVIDIA's intensified focus on photonics and strong community anticipation for breakthrough announcements. Investors and traders are actively discussing the company's wafer-scale technology as a pivotal solution for AI data center bottlenecks, further fueled by recent institutional endorsements and hints of significant customer engagements.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending as escalating Middle East tensions, including retaliatory strikes on energy infrastructure and a major Saudi refinery shutdown, ignite a surge in global oil prices. The community is actively discussing the potential for a prolonged conflict to drive significant upside for INDO, drawing comparisons to past commodity-driven rallies in low-float energy stocks.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is soaring amid a broad surge in the low-float oil and gas sector, driven by escalating Middle East tensions impacting crude prices. The community is heavily discussing its impressive momentum and potential for further short-squeeze action, while acknowledging the inherent volatility.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its highly active and dedicated community on Solana, which is relentlessly promoting the token as an "OG meme" with deep cultural roots from the early 2000s. This passionate "bagworking" is fueling strong bullish sentiment and calls for others to join before an anticipated significant rally.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending due to its recent acquisition of BrewDog assets for GBP 33M, a move dividing the community as some hail it as a strategic beverage diversification at a bargain, while others criticize investing in a struggling beer business. This comes as the broader cannabis sector anticipates potential U.S. rescheduling to Schedule III, prompting further debate over Tilray's core strategy as a Canadian LP.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid heightened geopolitical tensions, which are spotlighting the defense drone sector and fueling community discussions around the company's potential for significant military contracts for its Black Widow and FANG platforms. Investors are closely watching its participation in the Drone Dominance Program and upcoming Innovation Day for further clarity on future revenue and growth.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as softer CPI data reinforces community hopes for Fed rate cuts, driving demand for long-duration bonds, even as mixed inflation signals from PPI and heightened geopolitical tensions in the Middle East fuel a debate over safe-haven flows versus potential inflationary pressures.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

The recent regulatory setback for a key competitor's Cushing's drug is driving significant attention to Xeris Biopharma, further fueled by robust financial performance and the advancement of a major pipeline candidate into Phase 3. While the company demonstrates strong fundamentals and growth potential, community discussions reflect ongoing frustration with the stock's pronounced volatility despite these positive developments.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics (NTLA) is seeing significant investor attention and a surge in price after the FDA lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial. This development, coupled with high short interest, is fueling strong short squeeze sentiment and optimism among the community that the stock will return to prior levels, especially given discussions around the patient death being unrelated to the therapy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Urogen Pharma Q4 Earnings Call Highlights

Urogen Pharma (NASDAQ:URGN) executives used the company's fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product...

Urogen Pharma (NASDAQ:URGN) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and set a $33.00 target price on shares of Urogen Pharma in a research report on Monday...

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (NASDAQ:URGN) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Urogen Pharma (NASDAQ:URGN - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by...

UroGen Pharma: Q4 Earnings Insights

Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Monday

Urogen Pharma (NASDAQ:URGN) will be releasing its Q4 2025 earnings before the market opens on Monday, March 9. (View Earnings Report at...

Urogen Pharma (NASDAQ:URGN) Given Consensus Rating of "Moderate Buy" by Analysts

Urogen Pharma (NASDAQ:URGN - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat Ratings...

UroGen Pharma Earnings Preview

NEOS Investment Management LLC Acquires New Position in Urogen Pharma $URGN

NEOS Investment Management LLC acquired a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) during the third quarter, according to the company in its most recent Form 13F filing...

GSA Capital Partners LLP Invests $977,000 in Urogen Pharma $URGN

GSA Capital Partners LLP acquired a new stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The...

$URGN Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.54 up 32.50% YoY
• Reported revenue of $37.84M up 54.03% YoY

Stocktwits

UroGen Pharma Ltd

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of -$0.54 up 32.50% YoY
• Reported revenue of $37.84M up 54.03% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

URGN
UroGen Pharma Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest URGN News

URGNUroGen Pharma Ltd